BCX Stock Overview
Engages in the development of stem cell-based biopharmaceuticals for veterinary use.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bioceltix S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł64.90 |
| 52 Week High | zł98.00 |
| 52 Week Low | zł58.40 |
| Beta | 1.93 |
| 1 Month Change | -3.42% |
| 3 Month Change | -27.40% |
| 1 Year Change | -1.37% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 85.43% |
Recent News & Updates
Will Bioceltix (WSE:BCX) Spend Its Cash Wisely?
Jan 19
We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn Rate
Sep 21We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn Rate
May 09Shareholder Returns
| BCX | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -5.7% | -2.1% | -2.7% |
| 1Y | -1.4% | -18.1% | 24.5% |
Return vs Industry: BCX exceeded the Polish Biotechs industry which returned -18.1% over the past year.
Return vs Market: BCX underperformed the Polish Market which returned 24.5% over the past year.
Price Volatility
| BCX volatility | |
|---|---|
| BCX Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in PL Market | 9.2% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: BCX's share price has been volatile over the past 3 months.
Volatility Over Time: BCX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 28 | Lukasz Bzdzion | bioceltix.com |
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.
Bioceltix S.A. Fundamentals Summary
| BCX fundamental statistics | |
|---|---|
| Market cap | zł268.00m |
| Earnings (TTM) | -zł13.69m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-19.6x
P/E RatioIs BCX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCX income statement (TTM) | |
|---|---|
| Revenue | zł0 |
| Cost of Revenue | zł1.04m |
| Gross Profit | -zł1.04m |
| Other Expenses | zł12.65m |
| Earnings | -zł13.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 20, 2024
| Earnings per share (EPS) | -3.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BCX perform over the long term?
See historical performance and comparison